Sex hormone-binding globulin is a significant predictor of extracapsular extension in men undergoing radical prostatectomy

BJU International

Volumn 107, Issue 8, 2011, Pages 1243-1249

  Salonia, Andrea ^a   Gallina, Andrea ^a   Briganti, Alberto ^a   Zanni, Giuseppe ^a   Suardi, Nazareno ^a   Capitanio, Umberto ^a   Colombo, Renzo ^a   Bertini, Roberto ^a   Freschi, Massimo ^a   Guazzoni, Giorgio ^a   Rigatti, Patrizio ^a   Montorsi, Francesco ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

extracapsular invasion; prostate cancer; radical prostatectomy; sex hormone binding globulin; staging

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SEX HORMONE BINDING GLOBULIN;

ACCURACY; ADULT; AGED; ARTICLE; BODY MASS; CANCER INVASION; CANCER LOCALIZATION; CANCER STAGING; CONTROLLED STUDY; GLEASON SCORE; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RADICAL RETROPUBIC PROSTATECTOMY;

ADULT; AGED; BIOPSY; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PREOPERATIVE PERIOD; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; ROC CURVE; SEX HORMONE-BINDING GLOBULIN; TUMOR MARKERS, BIOLOGICAL;

EID: 79954498385     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09582.x     Document Type: Article

References (34)

1. Heidenreich A, Aus G, Bolla M, et al,. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80 (Pubitemid 350166735)
2. Isbarn H, Wanner M, Salomon G, et al,. Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era. BJU Int 2010; 106: 37-43
3. Makarov DV, Trock BJ, Humphreys EB, et al,. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007; 69: 1095-101 (Pubitemid 46891611)
4. Gallina A, Chun FK, Briganti A, et al,. Development and split-sample validation of a nomogram predicting the probability of seminal vesicle invasion at radical prostatectomy. Eur Urol 2007; 52: 98-105 (Pubitemid 46803017)
5. Shariat SF, Karakiewicz PI, Roehrborn CG, Kattan MW,. An updated catalogue of prostate cancer predictive tools. Cancer 2008; 113: 3075-99
6. Sankin A, Tareen B, Lepor H,. Side-specific factors associated with extracapsular extension and seminal vesicular invasion in men undergoing open radical retropubic prostatectomy. Prostate Cancer Prostatic Dis 2009; 12: 204-8
7. Bhojani N, Ahyai S, Graefen M, et al,. Partin Tables cannot accurately predict the pathological stage at radical prostatectomy. Eur J Surg Oncol 2009; 35: 123-8
8. Gallina A, Jeldres C, Chun FK, et al,. Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL. Eur Urol 2007; 52: 1374-80 (Pubitemid 47445969)
9. Chun FK, Suardi N, Capitanio U, et al,. Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsy. Eur Urol 2009; 55: 617-28
10. Bloch BN, Furman-Haran E, Helbich TH, et al,. Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging-initial results. Radiology 2007; 245: 176-85 (Pubitemid 47417801)
11. Svatek RS, Jeldres C, Karakiewicz PI, et al,. Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. Prostate 2009; 69: 886-94
12. Crawford ED,. Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. Urology 2009; 73 (Suppl.): S4-10
13. Isbarn H, Pinthus JH, Marks LS, et al,. Testosterone and prostate cancer: revisiting old paradigms. Eur Urol 2009; 56: 48-56
14. Weiss JM, Huang WY, Rinaldi S, et al,. Endogenous sex hormones and the risk of prostate cancer: a prospective study. Int J Cancer 2008; 122: 2345-50 (Pubitemid 351542341)
15. Grasso M, Buonaguidi A, Mondina R, et al,. Plasma sex hormone binding globulin in patients with prostatic carcinoma. Cancer 1990; 66: 354-7 (Pubitemid 20205919)
16. Lee SE, Chung JS, Han BK, et al,. Preoperative serum sex hormone-binding globulin as a predictive marker for extraprostatic extension of tumor in patients with clinically localized prostate cancer. Eur Urol 2008; 54: 1324-32
17. Salonia A, Briganti A, Gallina A, et al,. Sex hormone-binding globulin: a novel marker for nodal metastases prediction in prostate cancer patients undergoing extended pelvic lymph node dissection. Urology 2009; 73: 850-5
18. Green F, Page D, Fleming I,. American Joint Committee on Cancer Staging Manual 6th edn. New York: Sprinter, 2002
19. National Committee for Clinical Laboratory Standards. How to Define, Determine, and Utilize Reference Intervals in the Clinical Laboratory; Approved Guidelines. NCCLS Document C28-A. Villanova, PA: NCCLS, 1995: 59
20. Chun FK, Briganti A, Gallina A, et al,. Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium. Eur Urol 2007; 52: 1067-74
21. Lopergolo A, Zaffaroni N,. Biomolecular markers of outcome prediction in prostate cancer. Cancer 2009; 115 (Suppl.): 3058-67
22. Ulmert D, O'Brien MF, Bjartell AS, Lilja H,. Prostate kallikrein markers in diagnosis, risk stratification and prognosis. Nat Rev Urol 2009; 6: 384-91
23. Vermeulen A, Kaufman JM, Giagulli VA,. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. J Clin Endocrinol Metab 1996; 81: 1821-6 (Pubitemid 26152470)
24. Massengill JC, Sun L, Moul JW, et al,. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 2003; 169: 1670-5 (Pubitemid 36443468)
25. Imamoto T, Suzuki H, Fukasawa S, et al,. Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. Eur Urol 2005; 47: 308-12 (Pubitemid 40248848)
26. Morgentaler A, Traish AM,. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 2009; 55: 310-20
27. Sher DJ, Mantzoros C, Jacobus S, et al,. Absence of relationship between steroid hormone levels and prostate cancer tumor grade. Urology 2009; 73: 356-62
28. Eaton NE, Reeves GK, Appleby PN, Key TJ,. Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br J Cancer 1999; 80: 930-4 (Pubitemid 29233911)
29. Shappell SB, Fulmer J, Arguello D, Wright BS, Oppenheimer JR, Putzi MJ,. PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting. Urology 2009; 73: 363-8
30. Kristal AR, Schenk JM, Song Y, et al,. Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol 2008; 168: 1416-24
31. Whitman EJ, Groskopf J, Ali A, et al,. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol 2008; 180: 1975-9
32. de Ronde W, van der Schouw YT, Pierik FH, et al,. Serum levels of sex hormone-binding globulin (SHBG) are not associated with lower levels of non-SHBG-bound testosterone in male newborns and healthy adult men. Clin Endocrinol (Oxf) 2005; 62: 498-503
33. Lotan Y, Shariat SF, Khoddami SM, et al,. The percent of biopsy cores positive for cancer is a predictor of advanced pathological stage and poor clinical outcomes in patients treated with radical prostatectomy. J Urol 2004; 171: 2209-14 (Pubitemid 38625436)
34. Iczkowski KA, Hossain D, Torkko KC, et al,. Preoperative prediction of unifocal, unilateral, margin-negative, and small volume prostate cancer. Urology 2008; 71: 1166-71